CalciMedica, Inc. (CALC): Total Liabilities
$20.23M
As of 2025-12-31
$13.99M
As of 2026-06-30
+17.2%
3-year compound annual growth
+23.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.23M | +275.8% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $5.38M | +33.7% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $4.03M | -68.0% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $12.58M | +209.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $4.07M | -42.0% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $7.01M | -42.8% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $12.25M | n/a | 2021-03-05, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | 2025-12-31 | $20.23M | +275.8% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $1.48M | -56.9% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $123.69M | +8.4% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $6.11M | -33.7% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $10.12M | +22.1% |
| Biovie Inc. (BIVI) | 2026-06-30 | $3.98M | +56.1% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $5.03M | +115.6% |
| Propanc Biopharma, Inc. (PPCB) | 2026-06-30 | $3.38M | -41.0% |
Compare CALC, CMMB, CYDY, ACTU side by side · Screen every company in Pharmaceutical Preparations ↗